Skip to Content

Clinical Trials Details

Novartis CRAD001Y24135

Patient Information

Novartis CRAD001Y24135 - An open-label, Phase II Single-Arm study of Everolimus in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast Cancer

Find out more information about clinical trial - Novartis CRAD001Y24135

Study Number
CRAD001Y24135

Clinical Trial Categories

  • Breast Cancer - Metastatic

Also in this Section